Cell Dissociation Market Aims for US$ 1,257.59 Million by 2033

Analysts estimate that the cell dissociation market will reach a value of US$ 352.91 million by 2023 and expand at a compound annual growth rate (CAGR) of 13.55% from 2023 to 2033. By 2033, the cell dissociation industry is expected to generate US$1,257.59 million in revenue.

The Cell Dissociation Market plays a crucial role in various fields of life sciences and biotechnology by providing tools and reagents for the efficient separation of cells from tissues and cell aggregates. These dissociation methods are essential for a wide range of applications, including cell culture, cell analysis, and cell-based assays.

Cell dissociation enzymes, mechanical dissociation devices, and chemical dissociation reagents are some of the key products in this market. Researchers and scientists rely on these tools to obtain single-cell suspensions for downstream applications, such as flow cytometry, cell sorting, and gene expression analysis.

Seize Excellence Today: Claim Your Sample for Unmatched Efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16892

The market has seen significant growth in recent years due to the increasing demand for cell-based research and therapies. With advancements in regenerative medicine and the development of cell-based therapies, the Cell Dissociation Market is expected to continue expanding. Moreover, the ongoing research into cancer biology, stem cell biology, and immunology is driving the need for precise and gentle cell dissociation techniques, further fueling the market’s growth. As the life sciences field continues to evolve, the Cell Dissociation Market is well-positioned to provide critical tools for researchers and clinicians working on groundbreaking discoveries and therapies.

Synopsis of the Global Cell Dissociation Market

The cell dissociation industry is booming as a result of accelerated research and development spending by biopharmaceutical companies. Cell dissociation is an essential task in biopharmaceutical research as it’s directly involved in medicine creation and pathophysiology explanation.

The biopharmaceutical sector is a dynamically developing segment of the pharmaceutical industry, with significant consequences for healthcare. Opportunities in biopharmaceuticals have emerged in the previous decade as a result of their excellent efficacy and safety.

Many benefits of using biopharmaceuticals, including reduced side effects, and the possibility to treat the underlying cause of an illness have increased demand for medicines. There is growth in public and private investment due to the advent of products with better tissue dissociation enzymes. As a result, the cell dissociation industry flourished.

There are limited cell dissociation industry growth restrictions, despite the several significant market determinants. The cell dissociation industry growth may be constrained by soft tissue operations’ high cost.

Another factor that could slow the cell dissociation market growth is the preference for enzyme-free over enzymatic dissociation products.

Product Insight:

The cell dissociation market is categorized into enzymatic dissociation products, instruments & accessories, and non-enzymatic dissociation products. A range of enzymes is utilized in research for various purposes. Enzymatic dissociation products hold the lion’s market share.

Trypsin, collagenase, elastase, and hyaluronidase are often used in enzymatic dissociation products. Enzymes are deployed in stem cell research and cell biology studies for cell and tissue dissociation, and single-cell harvesting. The use of enzymes for cell dissociation is fairly prevalent.

Regional Viewpoint:

In 2023, North America is going to have a high-income share. Rising cancer and chronic illness, strong trend of research and development investments, acquisitions, and collaboration by companies are the factors driving the market growth in North America.

The rising frequencies of chronic diseases in developing countries and increased government initiatives strengthen market growth in the Asia Pacific. The emerging use of cell-based assays and the availability of low-cost cell lysis and dissociation solutions may spur market expansion.

Throughout the forecast period, Europe’s cell dissociation industry may account for the second leading revenue share. Europe’s established biotech and pharmaceutical enterprises may contribute to cell dissociation market growth.

Key Takeaways:

The enzymatic dissociation category is likely to lead the market, accounting for almost 47.90% of sales in 2023.
From 2023 to 2033, the non-enzymatic segment in the cell dissociation industry is likely to expand at a significant CAGR.
In 2023, the tissue dissociation type segment is dominant, accounting for 56.55% of the cell dissociation industry.
Throughout the predicted period, the cell detachment type segment may blossom at a swift CAGR.
In 2023, the pharmaceutical and biotechnology firms’ end-user segment is likely to dominate, accounting for 71.60% of the cell dissociation industry.
North America is likely to lead the cell dissociation industry, accounting for 37.20% of the market in 2023.
During the predicted period, Asia Pacific to exhibit a significant CAGR.

Economic Environment:

Leading cell dissociation manufacturers are investing in toxicity and efficacy investigations involving cell dissociation enzymes. This aspect is predicted to power substantial growth in the cell dissociation market during the forecast years.

To increase the industry footprint, cell dissociation manufacturers implement a variety of initiatives such as partnerships, mergers, acquisitions, and expansions.

Strategic Progressions for Cell Dissociation:

Acquisitions:

December 8, 2021

PPD, Inc., a prominent provider of clinical research services, was acquired by Thermo Fisher Scientific Inc. The acquisition was valued at around US$ 17.4 billion and designed to boost Thermo Fisher Scientific’s position in the life sciences sector.

April 9, 2020

Celsee, Inc., a leading manufacturer of single-cell analysis equipment, was acquired by Bio-Rad Laboratories, Inc. The acquisition sought to broaden Bio-Rad Laboratories’ product offerings in the single-cell analysis industry.

June 1, 2020

Becton, Dickinson, and Company purchased Straub Medical AG, a leading provider of medical equipment for the diagnosis and treatment of venous disorders. The acquisition sought to broaden Becton, Dickinson and Company’s product portfolio in the vascular access market.

Key Players: